Literature DB >> 6337697

Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone.

G P Murphy, S Beckley, M F Brady, T M Chu, J B deKernion, C Dhabuwala, J F Gaeta, R P Gibbons, S A Loening, C F McKiel, D G McLeod, J E Pontes, G R Prout, P T Scardino, J U Schlegel, J D Schmidt, W W Scott, N H Slack, M S Soloway.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6337697     DOI： 10.1002/1097-0142(19830401)51:7<1264::aid-cncr2820510716>3.0.co;2-u

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  19 in total

Review 1.  Does chemotherapy have a role before hormone-resistant disease develops?

Authors:  James P Dean; Celestia S Higano
Journal:  Curr Urol Rep       Date:  2009-05       Impact factor: 3.092

2.  Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.

Authors:  Chung Yao Yu; Bhushan Desai; Lingyun Ji; Susan Groshen; Hossein Jadvar
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-09-06

Review 3.  Flutamide. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in advanced prostatic cancer.

Authors:  R N Brogden; S P Clissold
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

Review 4.  Combination therapy in stage C and D prostatic cancer: rationale and five year clinical experience.

Authors:  F Labrie; A Dupont; A Bélanger; L Cusan; M Giguère; Y Lacourcière; I Luthy; D Bégin; C Labrie; J Simard
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer.

Authors:  T Braich; F R Ahmann; H S Garewal; A Robertone; S E Salmon
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Chemo-endocrine therapy for prostate cancer with bone metastasis. Nagasaki Prostate Cancer Research Group.

Authors:  H Sakai; Y Minami; H Kanetake; Y Saito
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Advances in the treatment of metastatic prostatic cancer.

Authors:  J S Elder; R P Gibbons
Journal:  West J Med       Date:  1985-09

Review 8.  Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.

Authors:  C M Perry; D McTavish
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 9.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

10.  Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.

Authors:  A V Schally; T W Redding
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.